Personalis reports Q4 2022 revenue $16.7M, net loss $31.1M; guides FY2023 revenue $68-72M

Personalis, Inc.

2022-FY EPS reported -$2.48 revenue$65,047,000

Q4 2022 revenue $16.7M, full year $65.0M; net loss Q4 $31.1M ($0.67/share), full year $113.3M ($2.48/share).
Cash and investments $167.7M at Dec 31, 2022; FY2023 cash usage guided to ~$75M, down from $119M in 2022.
Partnership with Moderna for genomic testing in personalized cancer vaccine trials; MRD validation study with Criterium and ABRCC.
Strategic review completed; new focus on MRD, personalized cancer vaccines, and pharma clinical trial support.
FY2023 net loss guided to ~$103M, improved from $113M in 2022 due to headcount reduction savings.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Personalis, Inc. reported the fourth quarter and full year ended December 31, 2022 results: revenue $16.7 million for the fourth quarter of 2022 and $65.0 million for the full year of 2022, net income Net loss of $31.1 million, and net loss per share of $0.67 ... in the fourth quarter 2022; net loss of $113.3 million, a, EPS $0.67 ... in the fourth quarter 2022; ... $2.48 ... in the full year 2022. Guidance initiated.

Period: the fourth quarter and full year ended December 31, 2022
Revenue: $16.7 million for the fourth quarter of 2022 and $65.0 million for the full year of 2022
Net income: Net loss of $31.1 million, and net loss per share of $0.67 ... in the fourth quarter 2022; net loss of $113.3 million, a
EPS: $0.67 ... in the fourth quarter 2022; ... $2.48 ... in the full year 2022
Guidance: initiated
Result: reported results

Exact text from the filing

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the fourth quarter and full year ended December 31, 2022

View on SEC.gov

Browse all earnings releases →

Personalis, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-004085

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.